{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:52:47Z","timestamp":1782795167822,"version":"3.54.5"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.hoc.2011.04.008","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T16:04:04Z","timestamp":1311437044000},"page":"835-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["mTOR Inhibitors in\u00a0Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Martin H.","family":"Voss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2011.04.008_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2011.04.008_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2011.04.008_bib4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9605","key":"10.1016\/j.hoc.2011.04.008_bib5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"9637","key":"10.1016\/j.hoc.2011.04.008_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2011.04.008_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2011.04.008_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2009.10.011","article-title":"Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth","volume":"36","author":"Gibbons","year":"2009","journal-title":"Semin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2011.04.008_bib9","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2011.04.008_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.hoc.2011.04.008_bib12","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1128\/MCB.22.15.5575-5584.2002","article-title":"The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation","volume":"22","author":"Peng","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.hoc.2011.04.008_bib13","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.2337\/diabetes.53.11.2748","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"issue":"16","key":"10.1016\/j.hoc.2011.04.008_bib14","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"issue":"Suppl 10","key":"10.1016\/j.hoc.2011.04.008_bib15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/cncr.24239","article-title":"Targeting mTOR in renal cell carcinoma","volume":"115","author":"Hudes","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2011.04.008_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-010-0141-x","article-title":"Targeting mTOR in cancer: renal cell is just a beginning","volume":"5","author":"Azim","year":"2010","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"issue":"5712","key":"10.1016\/j.hoc.2011.04.008_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"Pt 1","key":"10.1016\/j.hoc.2011.04.008_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1042\/bst0310292","article-title":"Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors","volume":"31","author":"Birkenkamp","year":"2003","journal-title":"Biochem Soc Trans"},{"issue":"14","key":"10.1016\/j.hoc.2011.04.008_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"issue":"50","key":"10.1016\/j.hoc.2011.04.008_bib22","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2","volume":"283","author":"Toschi","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gde.2006.12.006","article-title":"Hypoxia-inducible factors: central regulators of the tumor phenotype","volume":"17","author":"Gordan","year":"2007","journal-title":"Curr Opin Genet Dev"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib24","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1464-410X.2008.07558.x","article-title":"Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor","volume":"102","author":"Bhatt","year":"2008","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib26","first-page":"283","article-title":"Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas","volume":"36","author":"Lin","year":"2006","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib27","first-page":"346","article-title":"Activation of the mTOR signaling pathway in renal clear cell carcinoma","volume":"177","author":"Robb","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.hoc.2011.04.008_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cncr.25402","article-title":"The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases","volume":"117","author":"Abou Youssif","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2011.04.008_bib29","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization","volume":"28","author":"Sehgal","year":"1975","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610140102","article-title":"Rapamycin: a novel immunosuppressive macrolide","volume":"14","author":"Sehgal","year":"1994","journal-title":"Med Res Rev"},{"issue":"5","key":"10.1016\/j.hoc.2011.04.008_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors","volume":"37","author":"Eng","year":"1984","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","article-title":"Rapamycin is an effective inhibitor of human renal cancer metastasis","volume":"63","author":"Luan","year":"2003","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.hoc.2011.04.008_bib36","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2011.04.008_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cncr.20026","article-title":"Mammalian target of rapamycin inhibition as therapy for hematologic malignancies","volume":"100","author":"Panwalkar","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2011.04.008_bib38","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib39","first-page":"1758","article-title":"Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition","volume":"7","author":"Dudkin","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2011.04.008_bib40","first-page":"1527","article-title":"Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2011.04.008_bib41","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10637-009-9257-1","article-title":"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer","volume":"28","author":"Buckner","year":"2010","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1016\/j.hoc.2011.04.008_bib44","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2011.04.008_bib45","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A\u00a0phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2011.04.008_bib46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.04.008_bib47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2011.04.008_bib48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2011.04.008_bib49","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdq320","article-title":"Temsirolimus in VEGF-refractory metastatic renal cell carcinoma","volume":"22","author":"Mackenzie","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2011.04.008_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/jlts.2001.24645","article-title":"mTOR inhibitors: an overview","volume":"7","author":"Neuhaus","year":"2001","journal-title":"Liver Transpl"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2011.04.008_bib54","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2014renal transplantation","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib56","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib57","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data","volume":"26","author":"Tanaka","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2011.04.008_bib58","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A\u00a0phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2011.04.008_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1524-4733.2007.00183.x","article-title":"Development and validation of a scale to measure disease-related symptoms of kidney cancer","volume":"10","author":"Cella","year":"2007","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.hoc.2011.04.008_bib60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for\u00a0Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2011.04.008_bib61","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"Suppl 15","key":"10.1016\/j.hoc.2011.04.008_bib62","article-title":"First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Knox","year":"2010","journal-title":"Proc Am Soc Clinical Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl","key":"10.1016\/j.hoc.2011.04.008_bib64","article-title":"Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Molina","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.hoc.2011.04.008_bib65","article-title":"A\u00a0phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies","volume":"25","author":"Patnaik","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2011.04.008_bib66","article-title":"Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma","volume":"26","author":"Rosenberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.hoc.2011.04.008_bib67","article-title":"A\u00a0phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC)","volume":"29","author":"Kabbinavar","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.hoc.2011.04.008_bib68","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results","volume":"25","author":"Merchan","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.hoc.2011.04.008_bib69","article-title":"Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Result of the randomized TORAVA phase II trial","volume":"28","author":"Escudier","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.hoc.2011.04.008_bib70","article-title":"Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors","volume":"24","author":"Zafar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2011.04.008_bib71","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2011.04.008_bib72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A\u00a0randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2011.04.008_bib73","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.hoc.2011.04.008_bib74","article-title":"Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma","volume":"28","author":"Ravaud","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2011.04.008_bib75","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","article-title":"Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma","volume":"21","author":"Rodriguez-Pascual","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"14","key":"10.1016\/j.hoc.2011.04.008_bib76","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1074\/jbc.274.14.9351","article-title":"Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt\/phosphatidylinositol 3-kinase pathway","volume":"274","author":"Li","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"10.1016\/j.hoc.2011.04.008_bib77","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1073\/pnas.051042298","article-title":"A\u00a0phosphatidylinositol 3-kinase\/Akt\/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1","volume":"98","author":"Ozes","year":"2001","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1083\/jcb.200408161","article-title":"Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis","volume":"167","author":"Manning","year":"2004","journal-title":"J\u00a0Cell Biol"},{"issue":"8","key":"10.1016\/j.hoc.2011.04.008_bib79","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2011.04.008_bib80","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20142010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.hoc.2011.04.008_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2011.04.008_bib83","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1359-6349(09)71446-6","article-title":"Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"7","author":"Pablo","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib84","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.hoc.2011.04.008_bib85","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.hoc.2011.04.008_bib86","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1200\/JCO.2010.33.5984","article-title":"Everolimus- and temsirolimus-associated enteritis: report of three cases","volume":"29","author":"Parithivel","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2011.04.008_bib87","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.hoc.2011.04.008_bib88","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.hoc.2011.04.008_bib89","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","article-title":"Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways","volume":"111","author":"Tamburini","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib90","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.hoc.2011.04.008_bib91","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"issue":"Pt 1","key":"10.1016\/j.hoc.2011.04.008_bib93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A\u00a0complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"10.1016\/j.hoc.2011.04.008_bib94","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1016\/j.hoc.2011.04.008_bib95","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"Gupta","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.04.008_bib96","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.hoc.2011.04.008_bib97","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/13543784.2010.499121","article-title":"New inhibitors of the mammalian target of rapamycin signaling pathway for cancer","volume":"19","author":"Albert","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib98","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2011.04.008_bib99","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.24438","article-title":"Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha","volume":"115","author":"Figlin","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","article-title":"Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma","volume":"5","author":"Cho","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2011.04.008_bib101","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.hoc.2011.04.008_bib102","doi-asserted-by":"crossref","first-page":"e7887","DOI":"10.1371\/journal.pone.0007887","article-title":"Profiling critical cancer gene mutations in clinical tumor samples","volume":"4","author":"MacConaill","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.hoc.2011.04.008_bib103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.hoc.2011.04.008_bib104","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.eururo.2009.02.024","article-title":"Lack of KRAS and BRAF mutation in renal cell carcinoma","volume":"55","author":"Gattenlohner","year":"2009","journal-title":"Eur Urol"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2011.04.008_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0959-8049(05)80048-6","article-title":"Mutations in the ras protooncogenes are rare events in renal cell cancer","volume":"28","author":"Rochlitz","year":"1992","journal-title":"Eur J Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:56:46Z","timestamp":1760183806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858811000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0889858811000505"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2011.04.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR Inhibitors in\u00a0Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2011.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}